For consumers, however, the incentives look weaker. Credit cards offer rich rewards programs, while deposits and money-market funds pay interest. By contrast, the GENIUS Act explicitly prohibits ...

AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...

Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the ...

Recursion CEO Chris Gibson is out after 12 years as the ambitious "techbio" company positions itself for its next phase of AI drug discovery.

Salt Lake City, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board ...

Reports Q3 revenue $5.2M, consensus $19.36M. Cash, cash equivalents and restricted cash were $667.1M as of September 30, compared to $603.0M as of ...

With AI advancements upending the role of senior executives, the question is what the C-suite transformation should look like ...

This study offers a valuable advance for neuroscience by extending a visualization tool that enables intuitive assessment of how dendritic and synaptic currents shape the output of neurons. The ...